You realise the study was narrow scope, specifically looking at data for only up to 21 days after the second dose, it doesn’t account for events the after the first dose, doesn’t account for people who haven’t attended ER. the authors acknowledge it, no one claims this apart from you.If you were familiar with Clinical Papers you would know that authors are compelled to outline “limitations” of the research.
In this case, the limitations were not important enough for the Peer review process to reject the paper - they were inconsequential.
“Mycoarditis in young men is the most serious side effect at a rate of between 12-26/million depending on the mRNA Vaccine used.
That means the mRNA Vaccine is are over 99.999% safe in the highest risk cohort.”
Last edited: